TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06407232: Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Sponsor: University of Wisconsin, Madison · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 90 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$13,359,360

Rescue Site Savings

+$8,808,828

Unlock Full NCT06407232 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06407232 Rescue Dossier →